前列腺癌共病指数在预测根治性前列腺切除术男性死因特异性死亡中的验证
本研究在2000至2018年接受根治性前列腺切除术的4857例退伍军人前列腺癌患者中验证前列腺癌共病指数(PCCI)。结果显示PCCI评分越高,其他原因死亡风险呈阶梯式上升,10年累积发生率从8%至32%不等;PCCI 7分以上者90天全因死亡风险显著升高,而ASA评分未显示此关联。
要点
- PCCI评分越高,其他原因死亡风险呈阶梯式上升(PCCI 10+ vs 0:HR 4.99,95%CI 3.58-6.96)。
- PCCI 7分以上者90天全因死亡风险升高(OR 3.48,95%CI 1.26-9.63),ASA评分则无此关联。
- 较高PCCI评分与更差肿瘤结局相关,但关联主要由最高评分组驱动。
核心结论
- PCCI是根治性前列腺切除术后短期和长期其他原因死亡的稳健测量工具,已验证可用于临床医疗和以手术患者人群为重点的健康服务研究。
研究设计与样本
- 研究类型为验证性队列研究,样本为2000至2018年在VA接受根治性前列腺切除术的4857例前列腺癌患者。
- 采用Cox比例风险回归和逻辑回归评估PCCI评分与其他原因死亡、90天全因死亡、前列腺癌特异性死亡、转移和生化复发风险的关系。
- 比较PCCI与美国麻醉医师学会(ASA)评分对90天全因死亡的预测能力。
主要发现
- 中位随访6.7年(IQR 3.7-10.3),其他原因死亡风险随PCCI评分升高呈阶梯式增加,PCCI 1-2、3-4、5-6、7-9、10+相对于0的风险比(95%CI)分别为1.53(1.14-2.04)、2.11(1.55-2.88)、2.36(1.68-3.31)、3.61(2.61-4.98)、4.99(3.58-6.96)。
- 其他原因死亡10年累积发生率在PCCI评分0、1-2、3-4、5-6、7-9、10+组分别为8%、12%、16%、19%、26%、32%。
- PCCI 7分以上者90天全因死亡风险升高(OR 3.48,95%CI 1.26-9.63),而ASA评分较高者无此关联。
- 较高PCCI评分与更差肿瘤结局相关,最高评分组驱动了该关联。
临床怎么用
- 原文未据此给出推荐,仅指出PCCI已验证可用于临床医疗和以手术患者人群为重点的健康服务研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate prediction of competing risks of mortality remains a key component of prostate cancer treatment decision-making. We sought to validate the Prostate Cancer Comorbidity Index (PCCI) score for predicting other-cause mortality (OCM) and cancer outcomes in men undergoing radical prostatectomy (RP). MATERIALS AND METHODS: We sampled 4857 men with prostate cancer treated with RP in the VA from 2000-2018. Risks of OCM, 90-day all-cause mortality (ACM), prostate cancer-specific mortality, metastasis, and biochemical recurrence by PCCI score were assessed using Cox proportional hazards and logistic regression. We compared prediction of 90-day ACM between PCCI and the American Society of Anesthesiology (ASA) score, a validated predictor of short-term mortality. RESULTS: Over median follow-up of 6.7 years (IQR 3.7-10.3), there was a stepwise increase in risk of OCM with higher PCCI score, with hazards (95%CI) of 1.53 (1.14-2.04), 2.11 (1.55-2.88), 2.36 (1.68-3.31), 3.61 (2.61-4.98), and 4.99 (3.58-6.96) for PCCI 1-2, 3-4, 5-6, 7-9, and 10 + (vs. 0), respectively. Projected 10-year cumulative incidence of OCM was 8%, 12%, 16%, 19%, 26%, and 32% for scores of 0, 1-2, 3-4, 5-6, 7-9, and 10+ , respectively. Men with PCCI 7+ had greater odds of 90-day ACM (OR 3.48, 95%CI 1.26-9.63) while men with higher ASA did not. Higher PCCI score was associated with worse cancer outcomes, with the highest categories driving the associations. CONCLUSIONS: The PCCI is a robust measure of short- and long-term OCM after RP, validated for use in clinical care and health services research focusing on surgical patient populations.
引用
- Chen MS, Howard LE, Stock S, et al. Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy. Prostate Cancer Prostatic Dis. 2022. PMID: 35668181. doi:10.1038/s41391-022-00550-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。